Difference between revisions of "Pictilisib (GDC-0941)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
Warner-admin (talk | contribs) m (Text replacement - "http://www.cancer.gov" to "https://www.cancer.gov") |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
| − | From the [ | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=641462 NCI Drug Dictionary]: The orally bioavailable bismesylate salt of a potent small-molecule thieno[3,2-d]pyrimidine inhibitor of the class I phosphatidylinositol 3 kinase (PI3K) isoforms p100alpha and p100delta with potential antineoplastic activity. PI3K inhibitor GDC-0941 selectively binds to PI3K isoforms in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway. |
| − | + | ==Also known as== | |
| − | [[Category: | + | *'''Code name:''' GDC-0941 |
| + | |||
| + | [[Category:Drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | |||
| − | |||
| − | [[Category:Investigational]] | + | [[Category:PI3K alpha inhibitors]] |
| + | [[Category:PI3K delta inhibitors]] | ||
| + | |||
| + | [[Category:Investigational drugs]] | ||
Latest revision as of 20:20, 27 June 2024
Mechanism of action
From the NCI Drug Dictionary: The orally bioavailable bismesylate salt of a potent small-molecule thieno[3,2-d]pyrimidine inhibitor of the class I phosphatidylinositol 3 kinase (PI3K) isoforms p100alpha and p100delta with potential antineoplastic activity. PI3K inhibitor GDC-0941 selectively binds to PI3K isoforms in an ATP-competitive manner, inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and activation of the PI3K/Akt signaling pathway.
Also known as
- Code name: GDC-0941